Sei Investments Co. Sells 62,496 Shares of West Pharmaceutical Services, Inc. $WST

Posted by George Bondi on Jul 24th, 2026

Sei Investments Co. decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 10.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 529,261 shares of the medical instruments supplier’s stock after selling 62,496 shares during the period. Sei Investments Co.’s holdings in West Pharmaceutical Services were worth $132,654,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Darwin Wealth Management LLC lifted its holdings in West Pharmaceutical Services by 10.8% during the fourth quarter. Darwin Wealth Management LLC now owns 410 shares of the medical instruments supplier’s stock worth $113,000 after acquiring an additional 40 shares in the last quarter. IFM Investors Pty Ltd grew its stake in West Pharmaceutical Services by 0.3% in the first quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock valued at $3,452,000 after acquiring an additional 43 shares during the period. Aptus Capital Advisors LLC increased its holdings in shares of West Pharmaceutical Services by 5.5% in the fourth quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock worth $249,000 after acquiring an additional 47 shares in the last quarter. Cornerstone Planning Group LLC increased its holdings in shares of West Pharmaceutical Services by 90.9% in the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 50 shares in the last quarter. Finally, Benjamin Edwards Inc. raised its position in shares of West Pharmaceutical Services by 1.7% during the second quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier’s stock worth $661,000 after purchasing an additional 50 shares during the period. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services News Roundup

Here are the key news stories impacting West Pharmaceutical Services this week:

Positive Sentiment: West Pharmaceutical beat Q2 expectations, reporting adjusted EPS of $2.37 versus $2.08 expected and revenue of $872.3 million versus $840.0 million expected, showing solid demand across its business. West Reports Second-Quarter 2026 Results
Positive Sentiment: The company raised full-year 2026 guidance, now expecting EPS of $8.85 to $9.05 and revenue of $3.3 billion to $3.4 billion, both above prior expectations. West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
Positive Sentiment: Management pointed to strong demand for high-value products, including components tied to GLP-1, diabetes, obesity, and biologics drugs, which is helping drive growth and improve investor sentiment. West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
Neutral Sentiment: The company also issued Q3 guidance slightly above analyst estimates, reinforcing confidence in near-term momentum. West Pharmaceutical Raises 2026 Guidance After Strong Quarter

Insiders Place Their Bets

In other news, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the sale, the chief accounting officer owned 1,523 shares in the company, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the sale, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on WST. Evercore reiterated an “outperform” rating and set a $410.00 price objective on shares of West Pharmaceutical Services in a report on Monday, July 6th. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. KeyCorp lifted their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Finally, Wolfe Research began coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $363.17.

Check Out Our Latest Stock Analysis on WST

West Pharmaceutical Services Price Performance

Shares of WST opened at $355.25 on Friday. The stock has a market capitalization of $25.10 billion, a P/E ratio of 47.49, a P/E/G ratio of 2.90 and a beta of 1.16. West Pharmaceutical Services, Inc. has a twelve month low of $223.83 and a twelve month high of $386.00. The company has a 50 day moving average of $336.51 and a 200-day moving average of $287.14. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.West Pharmaceutical Services’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities research analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be issued a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.76%.

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.